Pharmaceutical

EMA CHMP endorses Mirum Pharmaceuticals’ LIVMARLI for PFIC

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended Mirum Pharmaceuticals’ LIVMARLI.

Jun 4, 2024 - 04:00
EMA CHMP endorses Mirum Pharmaceuticals’ LIVMARLI for PFIC
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended Mirum Pharmaceuticals’ LIVMARLI.
Read the original article

Tags:

Previous Article

CHMP approves backing for first acanthamoeba keratitis treatment

Next Article

Inline, real-time PAT tool is a game-changer for pharma granulation sector

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Johnson & Johnson gets grant for heart ultrasound image...

Apr 25, 2024

Diakonos’ brain tumour vaccine wins FDA’s orphan drug designation

Diakonos’ brain tumour vaccine wins FDA’s orphan drug d...

Jan 3, 2024

BioAegis scores $20m BARDA contract to develop ARDS therapy

BioAegis scores $20m BARDA contract to develop ARDS the...

Oct 17, 2023